SAGE-547 in severe postpartum depression

Phase 2, open-label, single-arm trial of brexanolone in postpartum depression (PPD), sponsored by Supernus Pharmaceuticals, Inc. Primary endpoints: Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Treatment Emergent Serious Adverse Events (TESAEs), Change From Baseline in Clinical Laboratory Measures (ALT, AST, GGT, CO2, Sodium, Potassium, Chloride, Glucose, Bilirubin, Calcium, BUN, Creatinine, Albumin, Protein, Hemoglobin, Hematocrit,… at Day 4 and 4 more. Started Jan 2015; status: completed.